Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in APL
NCT01409161Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2011
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of tretinoin, arsenic trioxide, gemtuzumab ozogamicin in acute promyelocytic leukemia (APL), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2011; status: recruiting.
02
Drugs
tretinoinarsenic trioxidegemtuzumab ozogamicin
03
Conditions
acute promyelocytic leukemia (APL)
Beyond the preview
Go deeper on NCT01409161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01409161.